

Review of: "[Research Note] Semaglutide, a GLP-1 Agonist Like Ozempic, and Its Potential Role as a Preventive Anti-Cancer Agent"

Ge Song¹

¹ University of South Carolina

Potential competing interests: No potential competing interests to declare.

The research note is well organized. However, I still have two concerns that are listed as follows.

1. The abstract mentions the word "Ozempic". However, the note has no description about Ozempic.
2. The last sentence of the first paragraph states that JAK-STAT is crucial. More descriptions about its importance can be mentioned after this sentence to make this note contain more information.